These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38560429)

  • 81. Long-Term Outcomes of Dose-Escalated Pelvic Lymph Node Intensity-Modulated Radiation Therapy (IMRT) With a Simultaneous Hypofractionated Boost to the Prostate for Very High-Risk Adenocarcinoma of the Prostate: A Prospective Phase II Clinical Trial.
    Hall WA; Bedi M; Kilari D; Bylow KA; Burfeind J; Johnstone C; Siker M; Currey A; See WA; Nelson A; Johnson S; Straza M; Lawton CAF
    Pract Radiat Oncol; 2021; 11(6):527-533. PubMed ID: 33848618
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer.
    Abu-Gheida I; Reddy CA; Kotecha R; Weller MA; Shah C; Kupelian PA; Mian O; Ciezki JP; Stephans KL; Tendulkar RD
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):325-333. PubMed ID: 30721720
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Biological impact of dosimetric perturbations of a fiducial marker and the daily number of fields in proton therapy for prostate cancer.
    Sagara T; Kato T; Murakami M
    Biomed Phys Eng Express; 2021 Jan; 7(2):025007. PubMed ID: 33522497
    [TBL] [Abstract][Full Text] [Related]  

  • 84. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer.
    Demanes DJ; Martinez AA; Ghilezan M; Hill DR; Schour L; Brandt D; Gustafson G
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1286-92. PubMed ID: 21310546
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland.
    Mohan DS; Kupelian PA; Willoughby TR
    Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):575-80. PubMed ID: 10701736
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A retrospective study of late adverse events in proton beam therapy for prostate cancer.
    Makishima H; Ishikawa H; Tanaka K; Mori Y; Mizumoto M; Ohnishi K; Aihara T; Fukumitsu N; Okumura T; Sakurai H
    Mol Clin Oncol; 2017 Oct; 7(4):547-552. PubMed ID: 29046789
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Time-Driven Activity-Based Costing of CT-Guided vs MR-Guided Prostate SBRT.
    Parikh NR; Clark MA; Patel P; Kafka-Peterson K; Zaide L; Ma TM; Steinberg ML; Cao M; Raldow AC; Lamb J; Kishan AU
    Appl Radiat Oncol; 2021 Sep; 10(3):33-40. PubMed ID: 34671700
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes.
    Berlin A; Cho E; Kong V; Howell KJ; Lao B; Craig T; Bayley A; Chung P; Gospodarowicz M; Warde P; Catton C; Bristow RG; Ménard C
    Pract Radiat Oncol; 2015; 5(5):e473-e482. PubMed ID: 25899220
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Protocol-based image-guided salvage brachytherapy. Early results in patients with local failure of prostate cancer after radiation therapy.
    Lahmer G; Lotter M; Kreppner S; Fietkau R; Strnad V
    Strahlenther Onkol; 2013 Aug; 189(8):668-74. PubMed ID: 23824103
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
    Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
    Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Preliminary result of carbon-ion radiotherapy using the spot scanning method for prostate cancer.
    Takakusagi Y; Katoh H; Kano K; Anno W; Tsuchida K; Mizoguchi N; Serizawa I; Yoshida D; Kamada T
    Radiat Oncol; 2020 May; 15(1):127. PubMed ID: 32460889
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Spot scanning proton therapy for malignancies of the base of skull: treatment planning, acute toxicities, and preliminary clinical outcomes.
    Grosshans DR; Zhu XR; Melancon A; Allen PK; Poenisch F; Palmer M; McAleer MF; McGovern SL; Gillin M; DeMonte F; Chang EL; Brown PD; Mahajan A
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):540-6. PubMed ID: 25304948
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Intraprostatic fiducials in stereotactic radiotherapy for prostate cancer].
    Cordoba A; Pasquier D; Nickers P; Lacornerie T; Lartigau É
    Cancer Radiother; 2016 Dec; 20(8):815-819. PubMed ID: 27793529
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Five-year follow-up using a prostate stent as fiducial in image-guided radiotherapy of prostate cancer.
    Carl J; Sander L
    Acta Oncol; 2015 Jun; 54(6):862-7. PubMed ID: 25539443
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Integration of a real-time tumor monitoring system into gated proton spot-scanning beam therapy: an initial phantom study using patient tumor trajectory data.
    Matsuura T; Miyamoto N; Shimizu S; Fujii Y; Umezawa M; Takao S; Nihongi H; Toramatsu C; Sutherland K; Suzuki R; Ishikawa M; Kinoshita R; Maeda K; Umegaki K; Shirato H
    Med Phys; 2013 Jul; 40(7):071729. PubMed ID: 23822433
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
    Dearnaley D; Syndikus I; Mossop H; Khoo V; Birtle A; Bloomfield D; Graham J; Kirkbride P; Logue J; Malik Z; Money-Kyrle J; O'Sullivan JM; Panades M; Parker C; Patterson H; Scrase C; Staffurth J; Stockdale A; Tremlett J; Bidmead M; Mayles H; Naismith O; South C; Gao A; Cruickshank C; Hassan S; Pugh J; Griffin C; Hall E;
    Lancet Oncol; 2016 Aug; 17(8):1047-1060. PubMed ID: 27339115
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
    Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
    J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Real-Time Gated Proton Therapy: Commissioning and Clinical Workflow for the Hitachi System.
    Chen H; Gogineni E; Cao Y; Wong J; Deville C; Li H
    Int J Part Ther; 2024 Mar; 11():100001. PubMed ID: 38757076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.